7 8 9	Display Items: 4/4 he Addiction Risk Factor: A Unitary Genetic Vulnerability Characterizes Substance Use Disorders and Their Associations with Common Correlates Alexander S. Hatoum <sup>1#</sup> , Emma C. Johnson <sup>1</sup> , Sarah M.C. Colbert <sup>1</sup> , Renato Polimanti <sup>2,3</sup> , Hang Zhou <sup>2,3</sup> , Raymond Walters <sup>4,5</sup> , Joel Gelernter <sup>2,3,6,7</sup> , Howard J. Edenberg <sup>8,9</sup> , Ryan Bogdan <sup>10</sup> * & Arpana Agrawal <sup>1</sup> *
7 8 9 10	<b>Disorders and Their Associations with Common Correlates</b> Alexander S. Hatoum <sup>1#</sup> , Emma C. Johnson <sup>1</sup> , Sarah M.C. Colbert <sup>1</sup> , Renato Polimanti <sup>2,3</sup> , Hang Zhou <sup>2,3</sup> , Raymond Walters <sup>4,5</sup> , Joel Gelernter <sup>2,3,6,7</sup> , Howard J. Edenberg <sup>8,9</sup> , Ryan Bogdan <sup>10</sup> * &
8 9 10	Alexander S. Hatoum <sup>1#</sup> , Emma C. Johnson <sup>1</sup> , Sarah M.C. Colbert <sup>1</sup> , Renato Polimanti <sup>2,3</sup> , Hang Zhou <sup>2,3</sup> , Raymond Walters <sup>4,5</sup> , Joel Gelernter <sup>2,3,6,7</sup> , Howard J. Edenberg <sup>8,9</sup> , Ryan Bogdan <sup>10</sup> * &
9 10 2	Zhou <sup>2,3</sup> , Raymond Walters <sup>4,5</sup> , Joel Gelernter <sup>2,3,6,7</sup> , Howard J. Edenberg <sup>8,9</sup> , Ryan Bogdan <sup>10</sup> * &
10 2	Zhou <sup>2,3</sup> , Raymond Walters <sup>4,5</sup> , Joel Gelernter <sup>2,3,6,7</sup> , Howard J. Edenberg <sup>8,9</sup> , Ryan Bogdan <sup>10</sup> * &
12	
13	
	Please send all correspondence to: Washington University School of Medicine, Department of
	ychiatry, 660 S. Euclid, CB 8134, Saint Louis, MO 63110, USA; email: <u>ashatoum@wustl.edu;</u>
16 Ph 17	ione: 903-539-7131
$18 ^{1}W$	Vashington University School of Medicine, Department of Psychiatry, Saint Louis, USA
19 <sup>2</sup> D	pepartment of Psychiatry, Division of Human Genetics, Yale School of Medicine, New Haven,
20 CT	Γ, USA
21 <sup>3</sup> V	eterans Affairs Connecticut Healthcare System, West Haven, CT, USA
22 <sup>4</sup> A	nalytic and Translational Genetics Unit, Department of Medicine, Massachusetts General
23 Но	ospital and Harvard Medical School, Boston, MA, USA
	tanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA,
	SA
	epartment of Genetics, Yale School of Medicine, New Haven, CT, USA
	epartment of Neuroscience, Yale School of Medicine, New Haven, CT, USA
	epartment of Medical and Molecular Genetics, Indiana University School of Medicine,
	dianapolis, IN, USA
	Department of Biochemistry and Molecular Biology, Indiana University School of Medicine,
	dianapolis, IN, USA
	Department of Psychological & Brain Sciences, Washington University in St. Louis
33 *T 34	These authors contributed equally to the work
34 35	

#### Hatoum 2

36	Abstract
37 38	Substance use disorders commonly co-occur with one another and with other psychiatric
39	disorders. They share common features including high impulsivity, negative affect, and lower
40	executive function. We tested whether a common genetic factor undergirds liability to
41	problematic alcohol use (PAU), problematic tobacco use (PTU), cannabis use disorder (CUD),
42	and opioid use disorder (OUD) by applying genomic structural equation modelling to genome-
43	wide association study summary statistics for individuals of European ancestry (Total N =
44	1,019,521; substance specific Ns range: 82,707-435,563), while adjusting for the genetics of
45	substance use (Ns = $184,765-632,802$ ). We also tested whether shared liability across SUDs is
46	associated with behavioral constructs (risk taking, executive function, neuroticism; Ns =
47	<b>328,339-427,037</b> ) and non-substance use psychopathology (psychotic, compulsive, and early
48	neurodevelopmental disorders). Shared genetic liability to PAU, PTU, CUD, and OUD was
49	characterized by a unidimensional addiction risk factor (termed The Addiction-Risk-Factor,
50	independent of substance use. OUD and CUD demonstrated the largest loadings, while
51	problematic tobacco use showed the lowest loading. The Addiction-Risk-Factor was associated
52	with risk taking, neuroticism, executive function, and non-substance psychopathology, but
53	retained specific variance before and after accounting for genetics of substance use. Thus, a
54	common genetic factor partly explains susceptibility for alcohol, tobacco, cannabis, and opioid
55	use disorder. The Addiction-Risk-Factor has a unique genetic architecture that is not shared with
56	normative substance use or non-substance psychopathology, suggesting that addiction is not the
57 59	linear combination of substance use and psychopathology.

58

#### Hatoum 3

## 59 **INTRODUCTION**

60

Substance use and use disorders (SUDs) represent large and growing public health problems that account for nearly 6% of global disease burden<sup>1</sup>. SUDs, both licit and illicit, commonly co-occur with each other and also with non-substance psychopathology; comorbidity is associated with increased symptom severity<sup>2</sup> and worse outcomes (e.g., less responsivity to treatment, greater socioeconomic costs<sup>3</sup>). However, the etiology underlying shared risk across these disorders is poorly understood.

67

### 68 Shared Genetic Liability

According to twin studies, the moderate-large heritability (50-60%) of distinct SUDs (i.e., alcohol, 69 70 nicotine, cannabis, and other illicit drugs) is partly attributable to a shared genetic vulnerability.<sup>4</sup> 71 Similarly, genetic correlations estimated from genome-wide association study (GWAS) data 72 support a shared genetic vulnerability between SUDs (e.g., SNP-rG = .73 between alcohol use disorder and opioid use disorder),<sup>5</sup> between SUDs and substance use (e.g., SNP-rG = .78 between 73 74 problematic alcohol use and drinks per week),<sup>6</sup> and between SUDs and psychopathology (e.g., 75 SNP-rG = .33 between cannabis use disorder and major depressive disorder<sup>7</sup>). What remains 76 unclear is the extent to which genetic liability across substance use *disorders* is *shared with* and 77 *distinct* from that of substance *use* (but not dependence) and non-substance psychopathology, and 78 what putative intermediate phenotypes may link shared genetic liability between SUDs and non-79 substance psychopathology.

80 *Substance Use and Use Disorder.* Substance use and SUDs have substantial genetic 81 overlap; however, genetic mechanisms that relate to SUD liability beyond normative or frequently 82 occurring substance use remain. For opioids<sup>8</sup>, alcohol<sup>9,10,11</sup>, and cannabis<sup>7</sup>, the use and use disorder

#### Hatoum 4

dimensions show differing associations with psychopathology (e.g. schizophrenia) and life
 outcomes (e.g. educational attainment)<sup>7,8,12,13</sup>.

85 Substance use and Psychopathology. Recently, Lee and colleagues<sup>14</sup> identified 3 broad 86 clusters (psychotic, compulsive, and early neurodevelopmental) representing shared and distinct genetic liability to 8 non-substance psychiatric disorders. While there has been limited integration 87 88 of substance use phenotypes into psychopathology models, polygenic liability to cross-diagnostic 89 vulnerability is associated with general substance use and SUDs<sup>15</sup>. Further, emerging evidence suggests partial overlap: tobacco use shares variance with ADHD<sup>16</sup>, alcohol and cannabis 90 dependence load with antisocial behavior<sup>17</sup>, and alcohol use and use disorder load together onto 91 an Externalizing factor<sup>18</sup>. Collectively, these data suggest that substance use and use disorders 92 93 share some common genetic liability with psychopathology.

94 Stage-Based Addiction Individual Differences and Substance Use Disorders. SUD 95 vulnerability has been conceptualized within a 3-stage neurobiological model consisting of binge/intoxication, preoccupation/anticipation, and withdrawal/negative affect<sup>19</sup>. In this model, 96 97 initial positive reinforcement is derived from stimulation of neural reward circuitry that drives 98 impulsive behaviors in the context of under-developed tolerance. With continued use and 99 progression towards SUD, the reinforcing properties of substances shift from positive to negative 100 reinforcement; as use becomes compulsive, it functions to return the body to drug-present 101 homeostasis and alleviate low mood, a predisposition to which is broadly indexed by 102 neuroticism<sup>20</sup>. Following repeated drug-reward and drug-homeostasis pairings, cognitive 103 preoccupation with the drug in expectation of reward/relief emerges in the context of impaired 104 executive functioning<sup>21</sup>. While GWASs support genetic correlations between SUDs and risk-

#### Hatoum 5

taking<sup>5,22</sup>, Executive Functioning<sup>23</sup>, and negative affect<sup>5,22</sup>, the extent to which common genetic
liability across SUDs relates to these constructs has yet to be examined.

### 107 **The Current Study**

108 Given evidence of shared liability to SUDs and other forms of psychopathology, understanding 109 the shared and unique genetic contributions to SUDs and how these relate to heritable proxies for 110 stage-based addiction constructs, non-substance psychopathology, and substance use may generate 111 etiologic insights that improve psychiatric nosology, prevention, and treatment. To this end, we 112 *first* estimate the shared genetic structure across SUDs by applying genomic structural equation modelling (gSEM)<sup>24</sup> to summary statistics generated by the largest GWAS of problematic alcohol 113 use (PAU)<sup>22</sup>, problematic tobacco use (PTU)<sup>25,26</sup>, cannabis use disorder (CUD)<sup>7</sup>, and opioid use 114 115 disorder (OUD)<sup>5</sup>. We name the shared variance across SUDs the Addiction-Risk-Factor. Second, 116 we relate the Addiction-Risk-Factor to genetics of behavioral constructs representing proxies of 117 the stage-based model of SUDs. We estimate the extent to which genetic liability to risk-taking, 118 executive function, and neuroticism are related to The Addiction-Risk-Factor. Third, we examine 119 whether The Addiction-Risk-Factor is associated with the 3 factors representing genetic liability 120 to non-substance psychopathology<sup>14</sup> (i.e., psychotic, compulsive, and neurodevelopment) and 121 whether stage-based addiction constructs (i.e., risk-taking, executive function, neuroticism) 122 indirectly link *The Addiction-Risk-Factor* to psychopathology. *Finally*, given that genetic liability 123 to substance use (e.g., ever using, quantity-frequency) and later stages of SUDs are partially 124 distinct<sup>7,12,13</sup>, we repeat all analyses while incorporating genetic liability to substance use (i.e., alcohol drinks/week<sup>26</sup>; tobacco ever regularly use<sup>26</sup>, cannabis ever use<sup>27</sup>) as covariates. 125

We hypothesized that SUDs and problem substance use would be largely characterized by a common genetic vulnerability (i.e., *The Addiction-Risk-Factor*) with evidence of potentially

#### Hatoum 6

128	important substance-specific liability (e.g., metabolic and signaling pathways for a specific drug
129	such as ADH1B variants with alcohol <sup>28</sup> ). We hypothesized that (i) The Addiction-Risk-Factor
130	would be associated with all 3 non-substance psychiatric clusters while retaining variance unique
131	to itself, (ii) genetic liability to behavioral phenotypes representing vulnerability to stage-based
132	addiction constructs (i.e., risk-taking, executive function, and neuroticism) would be associated
133	with The Addiction-Risk-Factor and account for a proportion of the association between The
134	Addiction-Risk-Factor and psychopathology factors, and (iii) after accounting for genetics of
135	substance use, The Addiction-Risk-Factor would retain unique variance (i.e., we expect significant
136	residual genetic correlations among SUDs) and maintain similar patterns with non-substance
137	psychopathology and stage-based constructs.

138

#### Hatoum 7

#### 139 METHODS

### 140 Samples

141 Summary statistics from the largest available discovery GWASs were used to represent genetic 142 risk for each construct (more details are in Supplemental Table 1). These include: i) 4 SUDs (problematic alcohol use<sup>22</sup>, problematic tobacco use<sup>25</sup>, cannabis use disorder<sup>7</sup>, opioid use 143 disorder<sup>5</sup>); ii) 3 substance use phenotypes (alcohol drinks/week<sup>26</sup>, lifetime ever smoking<sup>26</sup>, 144 145 lifetime cannabis use<sup>27</sup>); iii) 3 traits proxying the stage-based model of SUDs (risk-taking, 146 executive function, neuroticism); and iv) 9 non-substance psychiatric disorders. Analyses were 147 restricted to data from individuals of European ancestry because GWAS on these constructs in other ancestral origins are not available or are underpowered, and cross-ancestry analysis can 148 149 confound genetic correlation estimates<sup>29</sup>. All GWAS summary statistics were filtered to retain 150 variants with minor allele frequencies > 0.01 and INFO score > 0.90 for GSCAN and PGC<sup>7,26</sup> and 151 INFO score > 0.70 for the MVP<sup>5,30</sup>.

152

#### 153 Problematic Substance Use/Substance Use Disorder Summary Statistics

154 Problematic Alcohol Use: Summary statistics for problematic alcohol use (PAU) were derived

155 from a meta-analysis of GWASs of DSM-IV alcohol dependence from the Psychiatric Genomics

156 Consortium<sup>11</sup> (PGC-AD; n = 11,569 case, 34,999 controls), ICD-9/10 based diagnoses of alcohol

use disorders from the Million Veteran Program phase 1 and 2 data (MVP; n = 45,995 cases;

158 221,396 controls)<sup>9</sup> and the Problem subscale score from the Alcohol Use Disorders Identification

159 Test (AUDIT-P)<sup>13</sup> from the UK Biobank (n = 121,604)<sup>22</sup>. The final GWAS summary statistics

160 included data on 435,563 participants<sup>22</sup>. We also report on model fit with PGC-AD (instead of

161 PAU) in the supplement (Alternative Models, M1).

#### Hatoum 8

162	Problematic Tobacco Use (PTU): We used summary statistics from the GWAS of the
163	Fagerström Test for Nicotine Dependence <sup>25</sup> (FTND). As cigarettes per day is an item within the
164	FTND and the genetic correlation between FTND and cigarettes per day is high (calculated $rG =$
165	$0.97 \text{ CI} = .12)^{12}$ , we combined CPD And FTND into a single indicator. We applied Multi-Trait
166	Analysis of Genome-wide association study summary statistics (MTAG <sup>31</sup> ) to summary statistics
167	generated from the GWAS and Sequencing Consortium of Alcohol and Nicotine Use (GSCAN)
168	GWAS of cigarettes per day to create the combined problematic tobacco use (PTU) phenotype <sup>26</sup> .
169	The final GWAS summary statistics had an effective sample size of $n = 270,120$ individuals. We
170	also report on model fit with just FTND as an indicator in the supplement (Alternative Models
171	M2).
172	Cannabis Use Disorder (CUD): Summary statistics were derived from a GWAS meta-
173	analysis <sup>7</sup> of DSM-IV and DSM-III-R cannabis abuse and dependence from the Psychiatric
174	Genomics Consortium ( $n = 5,289$ cases; $n = 10,004$ controls), ICD-10 cannabis use disorder
175	from the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH) (n =
176	2,758 cases; $n = 53,326$ controls), and hospital-based diagnoses from deCODE ( $n = 6,033$ cases;
177	n = 280,396 controls). The final European-ancestry sample included 14,080 cases with CUD and
178	343,726 controls.
179	Opioid Use Disorder: Opioid use disorder (OUD): Summary statistics were derived from
180	a meta-analysis <sup>5</sup> of GWASs of DSM-IV opioid abuse or dependence from Yale-Penn, and the
181	Study of Addiction: Genetics and Environment, and ICD-9/10 codes for opioid use disorder from
182	the Million Veteran Program ( $n = 10,544$ cases; $n = 72,163$ opioid-exposed controls).
183	

# 184 Substance Use Summary Statistics

185	Alcohol use. Alcohol use summary statistics were derived from the GSCAN GWAS <sup>32</sup> for current
186	(this past week or average in the past year) reported drinks/week ( $n = 537,349$ ). There was a
187	strong correlation with lifetime PAU (SNP-rG between drinks/week and PAU = $0.77\pm0.02$ ) <sup>22</sup> .
188	Lifetime Tobacco Use. Summary statistics came from the GSCAN GWAS of reported
189	ever/never regular cigarette smoking (ever $n = 301,524$ , never $n = 331,278$ ). There was a
190	moderate correlation with PTU (SNP-rG = $0.28 \pm 0.03$ ).
191	Lifetime Cannabis Use. We used summary statistics from a meta-analysis of lifetime
192	cannabis ever-use from the International Cannabis Consortium and UK Biobank (ever n =
193	43,380; never $n = 118,702$ ) <sup>27</sup> . There was a moderate correlation with CUD <sup>7</sup> (SNP-rG =
194	0.47±0.05).
195	
196	Stage-based Behavioral Constructs
196 197	<b>Stage-based Behavioral Constructs</b> The three-stage behavioral model of addiction focuses on "state" changes in substance use
197	The three-stage behavioral model of addiction focuses on "state" changes in substance use
197 198	The three-stage behavioral model of addiction focuses on "state" changes in substance use behaviors. Because GWASs measure individual differences in traits, we selected behaviors that
197 198 199	The three-stage behavioral model of addiction focuses on "state" changes in substance use behaviors. Because GWASs measure individual differences in traits, we selected behaviors that (1) are known to convey vulnerability to each stage as proxies, and (2) are heritable.
197 198 199 200	The three-stage behavioral model of addiction focuses on "state" changes in substance use behaviors. Because GWASs measure individual differences in traits, we selected behaviors that (1) are known to convey vulnerability to each stage as proxies, and (2) are heritable. <i>Risk-taking and sensitivity to reward</i> . A GWAS of risk-taking derived from a single item
197 198 199 200 201	The three-stage behavioral model of addiction focuses on "state" changes in substance use behaviors. Because GWASs measure individual differences in traits, we selected behaviors that (1) are known to convey vulnerability to each stage as proxies, and (2) are heritable. <i>Risk-taking and sensitivity to reward</i> . A GWAS of risk-taking derived from a single item in the UK Biobank ("Would you describe yourself as someone who takes risks?"; data field
197 198 199 200 201 202	The three-stage behavioral model of addiction focuses on "state" changes in substance use behaviors. Because GWASs measure individual differences in traits, we selected behaviors that (1) are known to convey vulnerability to each stage as proxies, and (2) are heritable. <i>Risk-taking and sensitivity to reward</i> . A GWAS of risk-taking derived from a single item in the UK Biobank ("Would you describe yourself as someone who takes risks?"; data field #2040; risk taker n = 83,677; non-risk taker n = 244,662) <sup>33</sup> .
<ol> <li>197</li> <li>198</li> <li>199</li> <li>200</li> <li>201</li> <li>202</li> <li>203</li> </ol>	The three-stage behavioral model of addiction focuses on "state" changes in substance use behaviors. Because GWASs measure individual differences in traits, we selected behaviors that (1) are known to convey vulnerability to each stage as proxies, and (2) are heritable. <i>Risk-taking and sensitivity to reward</i> . A GWAS of risk-taking derived from a single item in the UK Biobank ("Would you describe yourself as someone who takes risks?"; data field #2040; risk taker n = 83,677; non-risk taker n = 244,662) <sup>33</sup> . <i>Executive Function</i> . The "preoccupation/anticipation" stage is characterized by

207	Negative Emotionality and Sensitivity to Stress. The stage of withdrawal/negative affect
208	represents substance use functioning to mitigate aversive withdrawal symptoms, such as negative
209	affect. Neuroticism has been found to modify stress sensitivity and neural reward processing <sup>35</sup> .
210	Neuroticism was chosen as a trait-based measure representing liability to negative affect as
211	opposed to depression because depression was included in the non-substance psychiatric disorder
212	factor generation and because neuroticism includes trans-diagnostic constructs such as negative
213	urgency (i.e., impulsive attempts to cope with negative affect) that may place individuals at risk
214	for the negative reinforcing aspects of SUDs. We selected the largest GWAS of neuroticism as a
215	heritable proxy (N = $390,278$ ) <sup>20</sup> .
216	Non-Substance Summary Statistics
217	Summary statistics from the PGC Cross-disorder GWAS on the 8 disorders that were
218	previously shown to fit a 3 factor confirmatory model were used <sup>14</sup> . These disorders included
219	Schizophrenia <sup>36</sup> , Bipolar disorder <sup>37</sup> , Major depressive disorder <sup>38</sup> , Attention Deficit Hyperactivity
220	disorder <sup>39</sup> , Obsessive Compulsive Disorder <sup>40</sup> , Anorexia Nervosa <sup>41</sup> , Tourette Syndrome <sup>42</sup> , and
221	Autism Spectrum Disorder <sup>43</sup> (See Supplemental Table 1 for details).
222	
223	Statistical analysis
224	First, we estimated the pairwise genetic correlations between PAU, PTU, CUD and OUD using
225	Linkage Disequilibrium Score Regression (LDSR) <sup>29</sup> . After confirming that the four SUDs were
226	significantly genetically correlated (see <b>Results</b> ), we applied confirmatory factor analysis to the
227	covariance matrix generated by LDSR using gSEM <sup>44</sup> with weighted least squares estimation;
228	PAU, PTU, OUD, and CUD indicators were allowed to load freely on a single latent factor (i.e.,
229	The Addiction-Risk-Factor). Variance of this common latent factor was scaled to 1.0. A residual

230	correlation between PAU and OUD was also estimated to account for measurement overlap,
231	because the Million Veterans Project sample was contained in both PAU and OUD GWAS (but
232	see model fit without this residual correlation in the supplement – Alternative Models M1). In
233	supplemental analyses, we also examined alternative two factor models (Alternative Models
234	M3).
235	Second, we used a series of structural regression models to estimate the extent to which
236	genetic liability to stage-based constructs of addiction (i.e., risk-taking, executive function and
237	neuroticism) are related to The Addiction-Risk-Factor. Here, the Addiction-Risk-Factor variance
238	was freed, and the OUD loading was set to 1.0 to scale the model. Intercorrelations were
239	estimated between risk-taking, executive function and neuroticism.
240	<i>Third</i> , we recreated the three factors from Lee et al <sup>14</sup> . (i.e., psychotic disorders,
241	compulsive disorders, and early neuro-developmental disorders) and estimated their relationship
242	with The Addiction-Risk-Factor while allowing for inter-factor correlations (the association
243	between The Addiction-Risk-Factor and an alternative cross-disorder genetic model from a
244	preprint <sup>45</sup> was also estimated; this alternative model is shown in <b>Supplemental Figure 5</b> ). This
245	allowed us to estimate the unique association between each of the 3 psychopathology factors and
246	The Addiction-Risk-Factor and to estimate variance that was residual to The Addiction-Risk-
247	Factor. We then examined whether proxies for stage-based addiction constructs (i.e., risk-taking,
248	executive function and neuroticism) indirectly linked The Addiction-Risk-Factor to the 3 non-
249	substance psychopathology factors using a multiple mediator model. We also conducted
250	supplemental modified Q-Trait analyses <sup>45</sup> to examine the extent of the mediation (Q-Trait
251	Analysis). To estimate residual associations (i.e., direct paths) between the stage-based
252	constructs and The Addiction-Risk-Factor, we re-structured the mediation model to one in which

253	the 3 non-SUD	psychopathology	factors served as	"mediators" o	of the relationship	between risk-

- taking, executive functioning, neuroticism, and *The Addiction-Risk-Factor*.
- 255 To separate the genetics of SUD from the genetics of substance use, we estimated models
- 256 where substance use GWAS summary statistics were endogenous predictors of all measured
- 257 variables in the model. For example, in the model estimating the association between *The*
- 258 Addiction-Risk-Factor and psychiatric factors, the 8 psychiatric disorders and the 4 SUD
- 259 disorder variables were regressed on the 3 substance use variables. In this way, covariate effects
- 260 were estimated simultaneously to our associations of interest.
- 261

#### Hatoum 13

### 262 **RESULTS**

#### 263 The Addiction Risk Factor

- 264 Genetic correlations between problematic alcohol use (PAU<sup>22</sup>), problematic tobacco use
- 265 (PTU<sup>25,26</sup>), cannabis use disorder (CUD<sup>7</sup>), and opioid use disorder (OUD<sup>5</sup>) ranged from 0.19
- 266 (S.E. = .04) to 0.78 (.09) (Supplemental Figure 1 and Supplemental Figure 2). PTU showed
- the lowest SNP-rG with other SUD phenotypes [i.e., PAU = 0.19 (.04), CUD = 0.31 (.05), OUD
- 268 = 0.26 (.08)] while OUD showed the highest [PAU = 0.69 (.07), CUD = 0.78 (.09)]. A
- 269 confirmatory factor model specifying a unidimensional Addiction-Risk-Factor underlying the
- 270 genetic covariance among PAU, PTU, CUD and OUD fit the data well  $[X^2(1) = .017, p = .895,$
- 271 CFI = 1, SRMR = .002; residual r = .51, p = 0.016; Figure 1A]. Loadings were uniformly high
- 272 except for PTU. Neither PAU nor PTU were impacted by the inclusion of non-diagnostic indices
- 273 of addiction risk (Supplemental Results Alternative Models M1-M2). Alternative 2-factor
- 274 models did not fit the data well (Alternative Models M3).

The inclusion of genetic liability to typical substance use did not modify the single factor structure of *The Addiction-Risk-Factor* (**Figure 1B**); all SUDs continued to load significantly on the factor. However, factor loadings were lower for all substances, especially for PAU, which may be attributable to the high genetic correlation between drinks/week and PAU. Alternative parameterization of substance use as covariates did not improve model fit (**Alternative Models M4**).

#### 281 Shared Liability to Stage-based Behavioral Phenotypes

282 Genetic liability to stage-based addiction constructs was shared with *The Addiction-Risk-Factor* 

283 (Figures 2, Q-Trait Analysis in Supplemental Methods). As expected, *The Addiction-Risk-*

*Factor* was positively associated with genetic liability to risk-taking ( $\beta = 0.45$ ) and neuroticism

Hatoum 14

285  $(\beta = 0.25)$ , and negatively associated with executive function ( $\beta = -0.17$ ; Figure 2A). Despite 286 significant genetic overlap between The Addiction-Risk-Factor and stage-based behavioral 287 phenotypes, The Addiction-Risk-Factor retained unique variance (Addiction-Risk-Factor residual 288 = 0.68). When conditioning for genetic liability for substance use, *The Addiction-Risk-Factor* 289 remained significantly associated with increased genetic liability to risk-taking ( $\beta = 0.22$ ) and 290 neuroticism ( $\beta = 0.18$ ) and decreased genetic liability to executive function ( $\beta = -0.28$ ; Figure 291 **2B**). Accounting for genetic liability for substance use substantially reduced the association 292 between *The Addiction-Risk-Factor* and risk-taking from 0.45 to 0.22 ( $p_{df=1} = 4e-09$ ) and 293 accentuated the negative association with executive function from  $\beta = -0.17$  to -0.28 (p<sub>(df = 1)</sub> = 294 0.013); there was a smaller effect on the association with neuroticism (from  $\beta = 0.25$  to 0.18, p<sub>(df</sub> 295 = 1) = 0.012).

296

#### 297 Shared Liability to Non-substance Psychopathology

298 Genetic liability to non-substance psychopathology (i.e., compulsive disorders, psychotic

299 disorders, and neurodevelopmental disorders) was shared with *The Addiction-Risk-Factor* 

300 (Figure 3, full models in Supplemental Figure 4; Supplemental Figure 5 shows results with

an alternative cross-disorder model from a recent preprint<sup>45</sup>). Psychotic disorders ( $\beta = 0.45$ ) and

302 neurodevelopmental disorders ( $\beta = 0.74$ ) were positively associated with *The Addiction-Risk*-

303 *Factor* while compulsive disorders showed a negative association ( $\beta = -0.32$ ; Figure 3A). Due to

304 the strong correlation between *The Addiction-Risk-Factor* and early-onset neurodevelopmental

305 disorders (which includes ADHD) we allowed ADHD to load on *The Addiction-Risk-Factor* to

306 control for ADHD; here, an association between *The Addiction-Risk-Factor* and early-onset

neurodevelopmental disorders remained, but was significantly attenuated (from  $\beta = 0.74$  to 0.43,

308	$p_{(df=1)} = 5e-5$ ). When conditioning <i>The Addiction-Risk-Factor</i> for substance <i>use</i> , the psychotic
309	and early neurodevelopmental disorder factors remained significantly associated with The
310	Addiction-Risk-Factor (Figure 3B). Despite the significant genetic overlap with other
311	psychiatric disorder domains, The Addiction-Risk-Factor retained unique variance representing
312	genetic liability specific to SUDs ( <i>The Addiction-Risk-Factor</i> residual = 0.30, p = 4.54e-3). This
313	unique variance remained significant when accounting for genetic liability to substance use (The
314	Addiction-Risk-Factor residual = $0.58$ , p = $0.015$ ).
315	The specifications for the mediation models are shown in Supplemental Figure 6.
316	Genetic liability to risk taking accounted for a proportion of the associations between all non-
317	substance psychopathology domains and The Addiction-Risk-Factor (Table 1). Executive
318	function uniquely indexed an indirect effect between psychotic disorders and The Addiction-
319	Risk-Factor (Table 1). When conditioning The Addiction-Risk-Factor for genetic liability to
320	substance use, risk-taking no longer accounted for a portion of the association between any non-
321	substance psychopathology domain and The Addiction-Risk-Factor, but executive function
322	continued to account for a proportion of the overlap (indirect effect of 0.048) between psychotic
323	disorders and The Addiction-Risk-Factor (Table 1). Post-hoc analyses revealed that executive
324	function retained a unique association with The Addiction-Risk-Factor after accounting for
325	genetic liability to both substance use and non-substance psychopathology (Supplementary
326	Table 2).
327	

#### Hatoum 16

#### 328 **DISCUSSION**

329 We applied genomic structural equation modeling (gSEM)<sup>24</sup> to GWAS summary statistics to 330 characterize the genetic influences shared across SUDs and estimate how common genetic 331 liability is related to trait conceptualizations of a theoretical stage-based SUD model as well as to 332 non-substance psychopathology. Three primary findings emerged. *First*, genetic risk for specific SUD phenotypes (i.e., PAU<sup>22</sup>, PTU<sup>25,26</sup>, CUD<sup>7</sup>, and OUD<sup>5</sup>) was largely attributable to a single 333 334 Addiction risk factor, The Addiction-Risk-Factor (Figure 1). Second, The Addiction-Risk-Factor 335 was associated with genetic liability to trait representations of stage-based facets of addiction 336 (risk taking [binge/intoxication], executive function [preoccupation/anticipation], neuroticism 337 [negative affect]<sup>19</sup>; **Figure 2**). It was also associated with non-substance psychopathology factors 338 (compulsive disorders, psychotic disorders, neurodevelopmental disorders; Figure 3). Trait 339 representations of stage-based facets of addiction partially accounted for the shared genetic 340 liability between non-substance psychopathology and *The Addiction-Risk-Factor*. Third, 341 associations between The Addiction-Risk-Factor and stage-based constructs and non-substance 342 psychopathology were largely independent of genetic liability to substance use phenotypes (i.e., 343 tobacco use, cannabis use, alcoholic drinks/week). However, consistent with the stage-based 344 model of addiction, accounting for substance use attenuated associations between risk taking and 345 The Addiction-Risk-Factor while potentiating associations with executive functioning. 346 Collectively, our findings suggest that SUDs are characterized by a common genetic factor, 347 Addiction-Risk-Factor.

348

349 The Addiction-Risk-Factor retains variance that is not shared with other psychopathology

350	After accounting for genetic liability to substance use as well as the commonality between The
351	Addiction-Risk-Factor and non-substance psychopathology, The Addiction-Risk-Factor retained
352	significant variance. These data suggest that The Addiction-Risk-Factor may be characterized by
353	unique pathways not shared with substance use or non-substance psychopathology, i.e., addiction
354	is not the linear combination of substance use and psychopathology.
355	A single latent factor, fit these data well, but specific SUDs showed varying degrees of
356	association. The illicit SUDs (CUD and OUD; Figure 1) were almost entirely captured by the
357	common latent factor. Notably, the loading for PTU on The Addiction-Risk-Factor was the
358	smallest. One potential contributor to the residual variance of PTU may be the use of FTND and
359	cigarettes/day as indices of PTU. Unlike the Diagnostic and Statistical Manual (DSM) criteria
360	which index psychological and physiological aspects of tobacco use disorder, the FTND is an
361	index of biochemical dependence and although used widely by investigators to define addiction,
362	phenotypically shows only moderate agreement with DSM-defined nicotine dependence (r =
363	0.50; kappa = $0.3$ ) <sup>46</sup> .
364	
365	Proxies of Stage-based Behavioral Constructs and The Addiction-Risk-Factor
366	Behavioral stage-based models of SUD posit a cyclical relationship between positive
367	reinforcement, negative reinforcement, and incentive salience <sup>19</sup> that we found can be (partially)
368	captured by genetic liability to risk-taking, executive functioning, and negative emotionality
369	(neuroticism). The strongest association with The Addiction-Risk-Factor was for risk-taking.
370	When substance use was included as a covariate in the model, the shared genetic loading
371	between The Addiction-Risk-Factor and both risk-taking and neuroticism was attenuated down
372	while the association with executive function increased. The reduction in the association with

373	neuroticism is counter to expectations from the stage-based model which posits a more
374	prominent role of negative affect for SUD relative to substance use. We speculate that
375	neuroticism, which represents an amalgam of negative affect traits, may be too broad a construct
376	when considering SUD-specific negative affect; large-scale studies of domains of negative
377	affectivity (e.g., negative urgency) are needed.
378	
379	Non-substance Psychopathology and The Addiction-Risk-Factor
380	We found that the 3 non-substance psychopathology clusters, derived from 8 psychiatric
381	disorders <sup>14</sup> , were genetically associated with <i>The Addiction-Risk-Factor</i> . The association with
382	early neurodevelopmental disorders, which include ADHD, was the strongest. Cross-loading
383	ADHD on The Addiction-Risk-Factor to condition on ADHD attenuated the loading but it
384	remained high. Associations between The Addiction-Risk-Factor and the psychopathology
385	clusters were greater than associations with trait representations of behavioral stages of addiction
386	(with the exception of risk-taking). For instance, the genetic association between The Addiction-
387	Risk-Factor and the two disorder clusters that included Major Depressive Disorder (i.e.,
388	psychotic disorders and early neurodevelopmental disorders) was greater in magnitude than the
389	Addiction-Risk-Factor-neuroticism association. Interestingly the compulsive disorder factor did
390	not show strong associations with The Addiction-Risk-Factor, suggesting that compulsive
391	disorders and addiction-related compulsive behaviors have distinct etiologies.
392	Of the 3 behavioral correlates, risk-taking was the most prominent contributor to the
393	association between The Addiction-Risk-Factor and all non-substance psychopathology factors.
394	After accounting for substance use, only risk-taking and executive function mediated The
395	Addiction-Risk-Factor associations with the psychotic disorder factor. Executive function

#### Hatoum 19

396	maintained the only direct association with The Addiction-Risk-Factor after accounting for
397	genetics of substance use and genetics of non-substance psychopathology. Thus, we speculate
398	that while risk-taking may characterize the genetic overlap between substance use and other
399	psychopathology, executive function impairment is a risk factor that not only shapes the overlap
400	between addiction and non-substance psychopathology but also explains variance in addiction
401	above and beyond that overlap.

402

#### 403 Limitations

404 There are several limitations. First, we had to restrict our analyses to individuals of European 405 descent due to the lack of well-powered discovery GWAS informative for other ancestry groups. 406 Second, to maximize sample size of discovery GWASs, our alcohol and tobacco use GWAS 407 incorporated measures of "problematic" use that, while genetically highly correlated with AUD 408 and ND, may include behavioral patterns that are less severe than those represented by use 409 disorder and were not assessed based on clinical presentation. Third, the analyses contain an 410 over-representation of men, in part because the MVP samples contributed most of OUD and half 411 of PAU and the MVP is ~90% male. Studies with larger numbers of women would allow 412 stratified analyses to explore the differences between sexes observed in epidemiological studies. 413 Fourth, while it is unlikely that individuals completed assessments of risk-taking, neuroticism, 414 and executive function while under the influence of substances, how substance use may have 415 influenced these assessments cannot be determined. Fifth, though significant, mediation 416 pathways were small in effect. Sixth, how these processes effect phenotypic patterns is unknown, 417 however twin studies support a common factor model as well<sup>4</sup>.

418

Hatoum 20

# 419 Conclusions

- 420 Common genetic liability undergirds distinct SUDs and shares variance with putative behavioral
- 421 intermediary phenotypes/SUD risk factors and non-substance psychopathology. This addiction
- 422 genetic factor is more than a linear combination of substance use and psychopathology; it
- 423 represents a unique addiction dimension that is partially captured by executive functions.

424

- 425 Funding. This research was supported by MH109532 (AA, JG, HJE, ECJ) and T32DA007261
- 426 (ASH). AA acknowledges K02DA32573. ECJ was supported by F32AA027435. RP
- 427 acknowledges R21DA047527. RB acknowledges R21-AA027827.
- 428 The Substance Use Disorders Working Group of the Psychiatric Genomics Consortium (PGC-
- 429 SUD) is supported by funds from NIDA and NIMH to MH109532. Disclosures/COI: JG is
- 430 named as an inventor on PCT patent application #15/878,640 entitled: "Genotype-guided dosing
- 431 of opioid agonists," filed January 24, 2018. The authors have no conflicts of interest.
- 432 Acknowledgments: We gratefully acknowledge our contributing studies and the participants in
- those studies without whom this effort would not be possible.
- 434 The MVP summary statistics were obtained via an approved dbGaP application
- 435 (<u>phs001672.v4.p1</u>). The authors thank Million Veteran Program (MVP) staff, researchers, and
- 436 volunteers, who have contributed to MVP, and especially participants who previously served
- their country in the military and now generously agreed to enroll in the study. (For details, see
- 438 https://www.research.va.gov/mvp/ and Gaziano, J.M. et al. Million Veteran Program: A mega-
- 439 biobank to study genetic influences on health and disease. J Clin Epidemiol 70, 214-23 (2016)).
- 440 This research is based on data from the Million Veteran Program, Office of Research and
- 441 Development, Veterans Health Administration, and was supported by the Veterans
- 442 Administration (VA) Cooperative Studies Program (CSP) award #G002.
- 443 This study included summary statistics of a genetic study on cannabis use (Pasman et al, 2018
- 444 Nature Neuroscience). We would like to acknowledge all participating groups of the
- 445 International Cannabis Consortium, and in particular the members of the working group
- 446 including Joelle Pasman, Karin Verweij, Nathan Gillespie, Eske Derks, and Jacqueline Vink.
- 447 Pasman et al, (2018) included data from the UK Biobank resource under application numbers
- 448 9905, 16406 and 25331.
- 449
- 450
- 451

Hatoum 22

# 452 **Reference Cited**

- Degenhardt, L. *et al.* The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Psychiatry* 5, 987–1012 (2018).
- Bhalla, I. P., Stefanovics, E. A. & Rosenheck, R. A. Clinical Epidemiology of Single
  Versus Multiple Substance Use Disorders. *Med. Care* 55, S24–S32 (2017).
- 458 3. Merikangas, K. R. & Kalaydjian, A. Magnitude and impact of comorbidity of mental
  459 disorders from epidemiologic surveys. *Current Opinion in Psychiatry* vol. 20 353–358
  460 (2007).
- 461 4. Palmer, R. H. C. *et al.* Genetic etiology of the common liability to drug dependence:
  462 evidence of common and specific mechanisms for DSM-IV dependence symptoms. *Drug*463 *Alcohol Depend.* 123 Suppl, S24-32 (2012).
- 464 5. Zhou, H. *et al.* Association of OPRM1 Functional Coding Variant with Opioid Use
  465 Disorder: A Genome-Wide Association Study. *JAMA Psychiatry* (2020)
  466 doi:10.1001/jamapsychiatry.2020.1206.
- 467 6. Sanchez-Roige, S., Palmer, A. A. & Clarke, T. K. Recent Efforts to Dissect the Genetic
  468 Basis of Alcohol Use and Abuse. *Biological Psychiatry* vol. 87 609–618 (2020).
- 469 7. Johnson, E. C. *et al.* A large-scale genome-wide association study meta-analysis of
  470 cannabis use disorder. *The Lancet Psychiatry* **0**, (2020).
- 8. Polimanti, R. *et al.* Leveraging genome-wide data to investigate differences between
  opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics
  Consortium. *Mol. Psychiatry* 25, 1673–1687 (2020).
- 474 9. Kranzler, H. R. *et al.* Genome-wide association study of alcohol consumption and use
  475 disorder in 274,424 individuals from multiple populations. *Nat. Commun.* 10, (2019).
- 476 10. Sanchez-Roige, S. *et al.* Genome-wide association study meta-analysis of the alcohol use
  477 disorders identification test (AUDIT) in two population-based cohorts. *Am. J. Psychiatry*478 **176**, 107–118 (2019).
- 479 11. Walters, R. K. *et al.* Transancestral GWAS of alcohol dependence reveals common
  480 genetic underpinnings with psychiatric disorders. *Nat. Neurosci.* 21, 1656–1669 (2018).
- 481 12. Sanchez-Roige, S., Cox, N. J., Johnson, E. O., Hancock, D. B. & Davis, L. K. Alcohol and cigarette smoking consumption as genetic proxies for alcohol misuse and nicotine
  483 dependence. *Drug Alcohol Depend.* 221, 108612 (2021).
- 484 13. Sanchez-Roige, S. *et al.* Genome-Wide Association Study Meta-Analysis of the Alcohol
  485 Use Disorders Identification Test (AUDIT) in Two Population-Based Cohorts. *Am. J.*486 *Psychiatry* **176**, 107–118 (2019).
- 487 14. Lee, P. H. *et al.* Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across
  488 Eight Psychiatric Disorders. *Cell* **179**, 1469-1482.e11 (2019).
- 489 15. Carey, C. E. *et al.* Associations between polygenic risk for psychiatric disorders and
  490 substance involvement. *Front. Genet.* 7, (2016).
- 491 16. Jang, S. K. *et al.* Genetic correlation, pleiotropy, and causal associations between
  492 substance use and psychiatric disorder. *Psychol. Med.* 1–11 (2020)
  493 doi:10.1017/S003329172000272X.
- 494 17. Waldman, I. D., Poore, H. E., Luningham, J. M. & Yang, J. Testing structural models of
  495 psychopathology at the genomic level. *World Psychiatry* 19, 350–359 (2020).
- 496 18. Karlsson Linnér, R. *et al.* Multivariate genomic analysis of 1.5 million people identifies
  497 genes related to addiction, antisocial behavior, and health. *Henry R. Kranzler* 17, 20

498		(2020).
499	19.	Goldstein, R. Z. & Volkow, N. D. Drug addiction and its underlying neurobiological
500		basis: Neuroimaging evidence for the involvement of the frontal cortex. American Journal
501		of Psychiatry vol. 159 1642–1652 (2002).
502	20.	Nagel, M., Watanabe, K., Stringer, S., Posthuma, D. & van der Sluis, S. Item-level
503	-01	analyses reveal genetic heterogeneity in neuroticism. <i>Nat. Commun.</i> <b>9</b> , 905 (2018).
504	21.	Koob, G. F. & Volkow, N. D. Neurobiology of addiction: a neurocircuitry analysis. <i>The</i>
505	21.	Lancet Psychiatry vol. 3 760–773 (2016).
506	22.	Zhou, H. et al. Genome-wide meta-analysis of problematic alcohol use in 435,563
507		individuals yields insights into biology and relationships with other traits. <i>Nat. Neurosci.</i>
508		1–10 (2020) doi:10.1038/s41593-020-0643-5.
509	23.	Hatoum, A. et al. GWAS of Over 427,000 Individuals Establishes GABAergic and
510		Synaptic Molecular Pathways as Key for Cognitive Executive Functions. GWAS Over
511		427,000 Individ. Establ. GABAergic Synaptic Mol. Pathways as Key Cogn. Exec. Funct.
512		674515 (2019) doi:10.1101/674515.
513	24.	Grotzinger, A. D. et al. Genomic structural equation modelling provides insights into the
514		multivariate genetic architecture of complex traits. <i>Nat. Hum. Behav.</i> <b>3</b> , 513–525 (2019).
515	25.	Hancock, D. B. et al. Genome-wide association study across European and African
516		American ancestries identifies a SNP in DNMT3B contributing to nicotine dependence.
517		Mol. Psychiatry 23, 1–9 (2018).
518	26.	Liu, M. <i>et al.</i> Association studies of up to 1.2 million individuals yield new insights into
519	-01	the genetic etiology of tobacco and alcohol use. <i>Nature Genetics</i> vol. 51 237–244 (2019).
520	27.	Pasman, J. A. <i>et al.</i> GWAS of lifetime cannabis use reveals new risk loci, genetic overlap
520	27.	with psychiatric traits, and a causal influence of schizophrenia. <i>Nat. Neurosci.</i> <b>21</b> , 1161–
522		1170 (2018).
523	28.	Edenberg, H. J. & McClintick, J. N. Alcohol Dehydrogenases, Aldehyde Dehydrogenases,
524	20.	and Alcohol Use Disorders: A Critical Review. <i>Alcoholism: Clinical and Experimental</i>
525		Research vol. 42 2281–2297 (2018).
526	29.	Bulik-Sullivan, B. K. <i>et al.</i> LD Score regression distinguishes confounding from
520 527	27.	polygenicity in genome-wide association studies. <i>Nat. Genet.</i> <b>47</b> , 291–295 (2015).
528	30.	Zhou, H. <i>et al.</i> Genome-wide meta-analysis of problematic alcohol use in 435,563
529	50.	individuals yields insights into biology and relationships with other traits. <i>Nat. Neurosci.</i>
530		<b>23</b> , 809–818 (2020).
531	31.	Turley, P. <i>et al.</i> Multi-trait analysis of genome-wide association summary statistics using
532	51.	MTAG. <i>Nat. Genet.</i> <b>50</b> , 229–237 (2018).
533	32.	Liu, M. <i>et al.</i> Association studies of up to 1.2 million individuals yield new insights into
534	52.	
	22	the genetic etiology of tobacco and alcohol use. <i>Nature Genetics</i> vol. 51 237–244 (2019).
535 526	33.	Strawbridge, R. J. <i>et al.</i> Genetics of self-reported risk-taking behaviour, trans-ethnic
536	24	consistency and relevance to brain gene expression. <i>Transl. Psychiatry</i> <b>8</b> , (2018).
537	34.	Volkow, N. D., Koob, G. F. & McLellan, A. T. Neurobiologic Advances from the Brain
538	25	Disease Model of Addiction. N. Engl. J. Med. <b>374</b> , 363–371 (2016).
539	35.	Bondy, E. <i>et al.</i> Neuroticism and reward-related ventral striatum activity: Probing
540	26	vulnerability to stress-related depression. (2020) doi:10.31234/osf.io/5wd3k.
541	36.	Schizophrenia Working Group of the Psychiatric Genomics Consortium, S. W. G. of the
542		P. G. <i>et al.</i> Biological insights from 108 schizophrenia-associated genetic loci. <i>Nature</i>
543		<b>511</b> , 421–7 (2014).

544	37.	Stahl, E. A. et al. Genome-wide association study identifies 30 loci associated with
545		bipolar disorder. Nat. Genet. 51, 793-803 (2019).
546	38.	Howard, D. M. et al. Genome-wide meta-analysis of depression identifies 102
547		independent variants and highlights the importance of the prefrontal brain regions. Nat.
548		<i>Neurosci.</i> <b>22</b> , 343–352 (2019).
549	39.	Demontis, D. et al. Discovery of the first genome-wide significant risk loci for attention
550		deficit/hyperactivity disorder. Nat. Genet. 51, 63-75 (2019).
551	40.	Arnold, P. D. et al. Revealing the complex genetic architecture of obsessive-compulsive
552		disorder using meta-analysis. Mol. Psychiatry 23, 1181–1188 (2018).
553	41.	Watson, H. J. et al. Genome-wide association study identifies eight risk loci and
554		implicates metabo-psychiatric origins for anorexia nervosa. Nat. Genet. 51, 1207–1214
555		(2019).
556	42.	Yu, D. et al. Interrogating the genetic determinants of Tourette's syndrome and other tiC
557		disorders through genome-wide association studies. Am. J. Psychiatry 176, 217–227
558		(2019).
559	43.	Grove, J. et al. Identification of common genetic risk variants for autism spectrum
560		disorder. Nat. Genet. 51, 431–444 (2019).
561	44.	Grotzinger, A. D. et al. Genomic SEM Provides Insights into the Multivariate Genetic
562		Architecture of Complex Traits. bioRxiv 305029 (2018) doi:10.1101/305029.
563	45.	Grotzinger, A. D. et al. Genetic architecture of 11 major psychiatric disorders at
564		biobehavioral, functional genomic, and molecular genetic levels of analysis. medRxiv vol.
565		18 18–19 (2020).
566	46.	Agrawal, A. et al. A latent class analysis of DSM-IV and fagerström (FTND) criteria for
567		nicotine dependence. Nicotine Tob. Res. 13, 972–981 (2011).
568		

	F1 Indirect %	F1 Indirect P	F2 Indirect %	F2 Indirect P	F3 Indirect %	F3 Indirect P
No covariates						
executive function	0.007	0.463	0.051*	0.001*	0.003	0.486
Neuroticism	0.005	0.842	0.003	0.836	0.013	0.777
Risk-taking	-0.090*	0.001*	0.152*	1.47E-08*	0.043*	0.013*
Controlling for (	Genetics of Substan	ce Use				
executive function	0.013	0.233	0.048*	0.047*	-0.007	0.491
Neuroticism	0.011	0.687	-0.022	0.693	-0.040	0.689
Risk-taking	0.001	0.509	0.019	0.446	-0.002	0.741

# Table 1. Behavioral Liabilities Mediate the Association Between The Addiction-Risk-Factor and Psychiatric Factors

**Table 1. Behavioral Liabilities Mediate the Association Between** *The Addiction-Risk-Factor* **and Psychiatric Factors** Indirect associations from a mediation model (see Figure 4) where stage-based constructs link non-substance psychopathology (3 factors from Lee et al.,) and *The Addiction-Risk-Factor*. F1 = compulsive disorders, F2 = Psychotic disorders, F3 = Neurodevelopmental disorders. The proportion accounted for by the indirect association (%) and the significance of the indirect

association are shown. \* P < .05 for the indirect association pathway.

**Figure 1. Factor Structure of 4 SUD GWAS. Panel A**: the model, loadings, and fit for a model that allowed all 4 SUD categories to load on a latent factor. A residual correlation was added between OUD and PAU to account for large sample overlap (both used the Million Veterans Project data; models without residual correlations also fit well: **Supplemental Figure 3**). *Addiction-rf=The Addiction Risk-Factor*. **Panel B**: the same model, but accounting for common substance use (ever smoke, ever use marijuana, and drinks per week) as covariates at the indicator level, i.e. the three substance use measures are exogenous to all indicators in this model and the model represents the residual associations after accounting for Substance use. Both models provided excellent fit to the data. **Bold\*** represents significance at p < .05. Note that in panel B, the residual of CUD is zero; this model constraint was necessary, as the model produced a negative residual without the constraint. Note: If you want to recreate the correlation matrix from both panels, the model with residual correlations cannot recover the implied correlation between PAU and OUD without taking the square root of the residual variance, rather than the value of the residual variance itself.

Figure 2. Genetic associations between *The Addiction-Risk-Factor* and behavioral traits: Executive Function, Neuroticism and Risk-taking. Panel A the model, fit, and regression pathways without accounting for common substance use. Panel B is the same model, but accounting for common substance use (ever smoke, ever use marijuana, and drinks per week) as covariates at the indicator level (regressed on all measured variables/GWAS). **Bold\*** represents significance at p < .05.

**Figure 3.** Genetic associations between *The Addiction-Risk-Factor* and Latent Psychopathology Factors: Compulsive disorders (F1; Tourette's syndrome, Obsessive compulsive disorder, and Eating Disorders), Psychotic Disorders (F2; Major Depressive Disorder, Schizophrenia, and Bipolar Disorder) and neurodevelopmental dysfunction (F3; ADHD, Autism, and Major Depressive Disorder). Panel A the model, fit, and regression pathways without accounting for common substance use (model was scaled by setting the Opioid Use Disorder loading to 1). Panel B is the same model, but accounting for common substance use (ever smoke, ever use marijuana, and drinks per week) as covariates at the indicator level (regressed on all measured variables/GWAS), i.e. the three substance use measures are exogenous to all indicators in this model and the model is the residual associations after accounting for substance use. **Bold\*** represents significance at p < .05. *Addiction-rf = The Addiction-Risk-Factor*.

1

# The Addiction Risk Factor: A Unitary Genetic Vulnerability Characterizes Substance Use Disorders and Their Associations with Common Correlates Supplemental Tables and Figures

Alexander S. Hatoum<sup>1#</sup>, Emma C. Johnson<sup>1</sup>, Sarah M.C. Colbert<sup>1</sup>, Renato Polimanti<sup>2,3</sup>, Raymond Walters<sup>4,5</sup>, Hang Zhou<sup>2,3</sup>, Substance Use Disorders Working Group of the Psychiatric Genomics Consortium, Joel Gelernter<sup>2,3,6,7</sup>, Howard J. Edenberg<sup>8,9</sup>, Ryan Bogdan<sup>10</sup>\* & Arpana Agrawal<sup>1\*</sup>

#Please send all correspondence to: Washington University School of Medicine, Department of Psychiatry, 660 S. Euclid, CB 8134, Saint Louis, MO 63110, USA; email: <u>ashatoum@wustl.edu</u>;

<sup>1</sup>Washington University School of Medicine, Department of Psychiatry, Saint Louis, USA <sup>2</sup>Department of Psychiatry, Division of Human Genetics, Yale School of Medicine, New Haven, CT, USA

<sup>3</sup>Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA

<sup>4</sup>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

<sup>5</sup>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA

<sup>6</sup>Department of Genetics, Yale School of Medicine, New Haven, CT, USA

<sup>7</sup>Department of Neuroscience, Yale School of Medicine, New Haven, CT, USA

<sup>8</sup>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA

<sup>9</sup>Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA

<sup>10</sup>Department of Psychological & Brain Sciences, Washington University in St. Louis \*These authors contributed equally to the work

# Index

Alternative Models Pg. 2 Q-Trait Analysis pg. 2-3 Supplemental Table 1 Pg. 4-7 Supplemental Table 2 Pg. 8 Supplemental Figure 1 Pg. 9 Supplemental Figure 2 Pg. 10 Supplemental Figure 3 Pg. 11 Supplemental Figure 4 Pg. 12 Supplemental Figure 5 Pg. 13 Supplemental Figure 6 Pg. 14-15

2

#### **Alternative Model specifications**

To establish our factor model, we tried several different approaches. First, we confirmed that the problematic alcohol use (PAU) and problematic tobacco use (PTU) variables did not significantly alter factor structure, as these are more proxies of the underlying construct of interest. Samples that are about an order of magnitude smaller are available for this exploration.

First, we reran the model with alcohol dependence from the Psychiatric Genetics Consortium GWAS of European descent (N= 38,686)<sup>1</sup> as the indicator for alcohol use disorder, instead of the larger problematic alcohol use (PAU) GWAS (Models M1). As the PGC alcohol dependence GWAS did not include data from the MVP, we also used this as an opportunity to test whether the residual genetic correlation between opioid use disorder (OUD) and alcohol dependence was present in the absence of measurement overlap. The model fit well ( $X^2 = 1.22$ , p = .54, df = 2, CFI = 1). When we tested the residual correlation, it was large although no longer significant (r=0.71, P=4.46e-01). The residual variance for alcohol dependence was also not significant (r=0.207 p=.51). As the alcohol dependence measure without MVP does not have a significant residual correlation, we posit that the need for the residual correlation when the MVP PAU summary data are used is to improve fit due to the larger sample or due to *measurement* overlap in the MVP.

Second, we tested whether inclusion of cigarettes per day with FTND created a poor proxy for tobacco dependence (Model M2). The model with FTND an indicator fit well, ( $X^2 = 0.027$ , p = .987, df = 2, CFI = 1) FTND indictor pathway was larger, but the confidence intervals overlapped substantially (r = .502, CI = .121).

For our next test of robustness, we conducted two follow-up analysis to examine whether parsing *Addiction-rf* into a two-factor structure improved fit (Models M3). The highest pairwise associations between SUD indicators were OUD with PAU. PTU with CUD also showed a high pairwise associations. Both factors were allowed to correlate. This model did not fit the data well (model fit:  $X^2 = 34.039$ , p = 1.94e-07, df = 3, CFI = .924, AIC = 47.039). We also fit a model where PAU and PTU loaded on one factor ("licit drugs") while CUD and OUD loaded on another correlated factor ("illicit drugs"). This model did not fit the data well either (model fit:  $X^2 = 293924.2$ , p = <.001, df = 5, CFI = .721.5134, AIC = 293934.2).

Next, there are two alternative models we tested to see if there was a more appropriate analysis to account for substance use (Models M4). To be clear, substance use is a covariate, but its covariate effect may be better modeled via alternative models. First, we generated a substance use factor using ever smoking regularly, marijuana use, and drinks per week as indicators. We then regressed the use disorder indicators on this factor. This model fit the data poorly. ( $X^2$ =394.4224, df=1, p=5.739041e-77 AIC=426.4224 CFI=0.8833732) and significantly worse than our original model ( $X^2$  diff=394.007, df=9, p=2e-64).

Next, rather than have the substance use variables endogenous to the indicators of addiction factor, we tested whether an alternative model where the indicators predicted the addiction factor directly fit the data better via a nested comparison. A model with the substance use variables predicting addition-*rf* fit the data poorly ( $X^2$ =324.481, df=10, P=1.025754e-63, AIC=360.481, CFI=0.9040932).

#### **Q-Trait Analysis**

3

*Background*. *Background*. Q-Trait analysis<sup>1</sup> was developed to test whether a latent genetic factor estimated using gSEM mediates the genetic association between an external trait (i.e., one not loaded onto the latent genetic factor) and factor indicators (those loading on the latent genetic factor). We conducted Q-trait analysis to test whether The Addiction-Risk-Factor accounts for genetic associations between these traits and each individual SUD indicator loading onto it (i.e., OUD, PAU, PTU, CUD). Q-Trait analysis evaluates this by comparing one model in which only the latent genetic factor is associated with the external trait to another model in which each indicator (i.e., the trait loading onto the genetic factor) is associated with the external trait. A  $\chi^2$  difference between these models is calculated and if there is a significant difference, it suggests that the genetic association between the external trait and the factor indicators are not accounted for by the latent genetic factor. However, this analysis is conducted with all factor indicators in a single model independent of the latent factor, and does not model scenarios in which the latent factor may differentially mediate (e.g., fully, partially, or not at all) individual factor indicators. Because of this limitation, in cases where we found no evidence that the latent genetic factor completely mediated the genetic association between the external trait and factor indicators (i.e., when there was a significant  $\gamma^2$  difference), we conducted a series of post-hoc models regressing the latent genetic factor and each individual genetic indicator on the external traits in an iterative processes (For example, a model in which the latent genetic Addiction-Risk-*Factor* and problematic tobacco use were regressed on executive function).

Results. Q-Trait analysis revealed that the latent genetic Addiction-Risk-Factor mediated associations between risk-taking and individual SUD indicators, as indicated by a lack of significance in model fit ( $X^2 diff(3) = 6.478$ , P=0.091). Although initial Q-trait modeling provided no evidence that the latent genetic Addiction-Risk-Factor accounted for associations between individual SUD indicators with executive function ( $X^2 diff(3) = 25.7$ , P = 1.00e-5) and neuroticism ( $X^2 diff(3) = 625.7$ , P=1.00e-5), post-hoc analyses revealed that the lack of evidence for mediation is attributable to differential mediation across indicators. Executive function is correlated with The Addiction-Risk-Factor, but shows stronger associations with problematic alcohol use, cannabis use disorder, and opioid use disorder than problematic tobacco use (see Supplemental Table 1). Because of this we tested an additional model wherein the latent genetic Addiction-Risk-Factor and problematic tobacco use were regressed on executive function simultaneously, which revealed no significant difference from the model in which all individual SUD indicators were included ( $X^2 diff(2) = 4.635$ , P = .0985), suggesting that the common latent Addiction-Risk-Factor mediates associations between executive function and PAU, OUD, and CUD, but not PTU. Further, additional regression path greatly bolstered upward the association *between The Addiction-Risk-Factor* and executive function (r=-.31, p=1.00e-17). For neuroticism, the addition of specific paths with PAU and CUD in addition to The Addiction-Risk-Factor revealed evidence that the latent genetic factor mediates associations with OUD and PTU  $(X^2 diff(1) = 2.798, P=0.0944)$ . However, this did not change the association with the latent factor (r=.20, p=7.08e-3); it is simply that neuroticism has associations with PAU and CUD that are independent of The Addiction-Risk-Factor.

*Interpretation for downstream analysis.* Downstream analysis did not retain these specific associations. For executive functioning, we still found significant associations between cEF and addiction risk, and mediating pathways despite the association being attenuated downward by our chosen model. Neuroticism did not maintain mediating pathways, and so

improving the model would not have led to additional discovery power for the neuroticism phenotype.

		N (FUD)	SNP-h2 (SE)	Link		
		(EUR)	Substance use die	ordoro		
Problematic	Substance use disorders         Problematic       Meta-analysis       435,563       0.068(0.004)       PMID: 32451486					
alcohol use	Meta-analysis of DSM-IV	455,505	0.008(0.004)	FMID. 52451460		
(PAU)	alcohol					
(1 AU)	dependence,					
	ICD9/10					
	coded alcohol					
	use disorder,					
	and problem					
	subscale					
	scores from					
	the AUDIT					
Problematic	MTAG	270,120	0.076(0.007)	PMC6358542		
Tobacco Use	analysis					
(PTU)	combining					
	FTND GWAS					
	with GWAS					
	of cigarettes					
Cannabis Use	per day	257.906	120(0.010)	PMC5882602		
Disorder	Meta-analysis of DSM-IV	357,806	.120(0.010)	PMC3882002		
(CUD)	and ICD9/10					
(COD)	coded					
	cannabis abuse					
	and					
	dependence					
Opioid Use	Meta-analysis	82,707	0.113(0.018)	PMC7270886		
Disorder	of ICD9/10					
(OUD)	and DSM-IV					

# Table 1. GWAS summary statistics used in this study.

	coded opioid					
	use disorder		Cubatanaa L			
A 1 1 - 1	Substance Use					
Alcohol drinks per week	Meta-analysis of self- reported drinks per week by GSCAN	537,349	0.042(0.002)	<u>PMC6358542</u>		
Ever smoking cigarettes	Meta-analysis of self- reported ever smoking by GSCAN	632,802	.078(0.002)	<u>PMC6358542</u>		
Cannabis use	Meta-analysis of any lifetime cannabis use	184,765	0.11(0.001)	<u>PMC6386176</u>		
			Stage-based behavior	al correlates		
Risk-taking	GWAS of self-reported risk-taking	328,339	0.055(0.003)	PMC6123450		
Executive function	Common Factor of multiple executive functioning tasks	427,037	0.104(0.002)	https://www.biorxiv.org/content/10.1101/674515v2.full.pdf		
Neuroticism	GWAS meta- analysis of trait neuroticism	390,278	0.100(0.003)	PMID: 29942085		
Other Psychiatric Disorders						

ADHD	GWAS meta- analysis of	53,293	0.222(0.014)	<u>PMC6481311</u>
	ADHD			
	diagnosis from			
	the PGC			
Anorexia	GWAS meta-	72,517	0.110(0.01)	<u>PMC6779477</u>
Nervosa	analysis of			
	Anorexia			
	Nervosa from			
	the PGC	46.050	112(0.010)	
Autism	GWAS meta-	46,350	.113(0.010)	<u>PMC6454898</u>
	analysis of Autism from			
	the PGC			
Bipolar	GWAS meta-	51,710	0.182(0.011)	PMC6956732
Disorder	analysis of	51,710	0.182(0.011)	<u>1 WC0950752</u>
Disolder	Bipolar			
	disorder			
	diagnosis from			
	the PGC			
MDD	GWAS meta-	480,359	0.089(0.003)	PMC6522363
	analysis of			
	self-reported			
	Major			
	Depression			
	Diagnosis			
	from the PGC			
OCD	GWAS meta-	9,725	0.280(0.041)	PMC6660151
	analysis of			
	Obsessive			
	Compulsive			
	Disorder			

	Diagnosis from the PGC			
Schizophrenia	GWAS meta- analysis of Schizophrenia diagnosis from the PGC	77,096	0.222(0.012)	<u>PMC4112379</u>
Tourette Syndrome	GWAS meta- analysis of Tourette Syndrome diagnosis from the PGC	13,340	0.200(0.026)	<u>PMC6677250</u>

Supplementary Table 2. Direct Associations between behavioral correlates and the Addiction Risk Factor – *Addiction-rf* - beyond non-substance psychopathology


	Direct Beta on Addiction-rf	P-value						
No covariates								
Executive Function	-0.101*	0.004						
Neuroticism	-0.009	0.874						
Risk-taking	0.261*	1.60e-8						
Controlling for Geneti	cs of Substance Use							
Executive Function	-0.122*	0.018						
Neuroticism	0.048	0.578						
Risk-taking	0.057	0.307	0.307					

## Supplementary Table 2. Behavioral Liabilities Mediate the Association Between -Factor and Psychiatric Factors

Indirect associations from a mediation model (see Figure 4) where stage-based constructs link non-substance psychopathology (three factors from Lee et al.,) and *The Addiction-Risk Factor* (*Addiction-rf*). Indirect association is represented by the proportion accounted for by the indirect association (%) and the significance of the indirect association. F1 =compulsive disorders, F2 =Psychotic disorders, F3 =Neurodevelopmental disorders.

FormerSmoke	-0.38	-0.29	-0.44	-0.31	0.04	-0.37	-0.09	0.01	-0.23	-0.18	0.01	0.06	-0.35	0.12	0.19	-0.19	-0.21	-0.39	-0.1	0.16	0.29	1	
AgeSmoke	-0.34	-0.3	-0.38	-0.55	0.18	-0.61	-0.02	0.01	-0.26	-0.24	-0.12	0.25	-0.38	0.05	0.15	-0.25	-0.18	-0.69	-0.16	-0.06	1	0.29	
MJUse	0.21	0.4	-0.07	0.48	0.23	0.17	0.25	0.28	0.18	0.21	-0.05	0.04	0.18	0.21	0.03	0.42	-0.01	0.53	0.4	1	-0.06	0.16	
DPW	0.39	0.79	0.09	0.34	0	0.16	0.08	0.12	0.08	0.07	-0.03	0.07	-0.08	0.05	-0.06	0.27	0.05	0.42	1	0.4	-0.16	-0.1	
EverSmoke	0.49	0.53	0.3	0.65	-0.04	0.57	0.13	0.08	0.31	0.31	0.03	-0.21	0.36	-0.01	-0.08	0.32	0.18	1	0.42	0.53	-0.69	-0.39	
NE	0.16	0.29	0.14	0.12	0.27	0.26	0.19	0.12	0.74	0.81	0.18	0.27	0.6	0.19	-0.22	-0.05	1	0.18	0.05	-0.01	-0.18	-0.21	
Risk	0.24	0.3	0.21	0.43	0.01	0.39	0.24	0.3	0.15	0.05	-0.05	-0.1	0.33	-0.05	-0.11	1	-0.05	0.32	0.27	0.42	-0.25	-0.19	
EF	-0.36	-0.18	0	-0.25	-0.13	-0.19	-0.35	-0.26	-0.18	-0.21	-0.05	-0.15	-0.23	0.01	1	-0.11	-0.22	-0.08	-0.06	0.03	0.15	0.19	
Autism	-0.12	0.02	-0.03	0.03	0.06	0.08	0.21	0.07	0.15	0.22	0.1	0.06	0.09	1	0.01	-0.05	0.19	-0.01	0.05	0.21	0.05	0.12	
PTSD	0.5	0.39	0.45	0.45	0.22	0.64	0.32	0.21	0.71	0.61	-0.09	0.07	1	0.09	-0.23	0.33	0.6	0.36	-0.08	0.18	-0.38	-0.35	Correlation Coefficient
TS	0.03	0.03	-0.12	-0.06	0.46	-0.15	0.34	0.34	0.26	0.37	0.43	1	0.07	0.06	-0.15	-0.1	0.27	-0.21	0.07	0.04	0.25	0.06	0.5
OCD	-0.05	-0.02	0.08	0.05	0.1	0.22	0.08	0.07	0.22	0.26	1	0.43	-0.09	0.1		-0.05	0.18	0.03	-0.03	-0.05	-0.12	0.01	0.0
GAD	0.37	0.35	0.21	0.36	0.34	0.4	0.34	0.26	0.9	1	0.26	0.37	0.61	0.22	-0.21	0.05	0.81	0.31	0.07	0.21	-0.24	-0.18	0.5
MDD	0.35	0.37	0.23	0.32	0.28	0.46	0.31	0.34	1	0.9	0.22	0.26	0.71	0.15	-0.18	0.15	0.74	0.31	0.08	0.18	-0.26	-0.23	-1.0
BiP	0.16	0.29	0.07	0.18	0.13	0.11	0.68	1	0.34	0.26	0.07	0.34	0.21	0.07	-0.26	0.3	0.12	0.08	0.12	0.28	0.01	0.01	
Scz	0.29	0.3	0.09	0.3	0.24	0.13	1	0.68	0.31	0.34	0.08	0.34	0.32	0.21	-0.35	0.24	0.19	0.13	0.08	0.25	-0.02	-0.09	
ADHD	0.36	0.32	0.46	0.5	0	1	0.13	0.11	0.46	0.4	0.22	-0.15	0.64	0.08	-0.19	0.39	0.26	0.57	0.16	0.17	-0.61	-0.37	
ED	0.31	0.11	-0.1	0.01	-	0	0.24	0.13	0.28	0.34	0.1	0.46	0.22	0.06	-0.13	0.01	0.27	-0.04	0	0.23	0.18	0.04	
CUD	0.77	0.54	0.33	1	0.01	0.5	0.3	0.18	0.32	0.36	0.05	-0.06	0.45	0.03	-0.25	0.43	0.12	0.65	0.34	0.48	-0.55	-0.31	
Tob	0.3	0.21	1	0.33	-0.1	0.46	0.09	0.07	0.23	0.21	0.08	-0.12	0.45	-0.03	0.20	0.21	0.12	0.3	0.09	-0.07	-0.38	-0.44	
PAU	0.71	1	0.21	0.55	0.11	0.32	0.03	0.29	0.23	0.21	-0.02	0.03	0.39	0.02	-0.18	0.21	0.29	0.53	0.03	0.4	-0.3	-0.29	
OUD	0.71	0.71	0.21	0.34	0.31	0.32	0.29	0.29	0.37	0.35	-0.02		0.59		-0.16	0.3	0.29	0.33	0.79	0.4	-0.34	-0.29	
(	JUP .	8R)	100	-ju <sup>V</sup>	EV A	OHID	SCL	Bilt	NDD (	3AV (	SCV	19	SV A	HISM	<i>4</i> ,	Rist	Alt St	note <	SPUN N	ADESS	notest	note	
																	ENE			P02 40	noke		


Supplementary Figure 1. Genetic correlations (SNP-rG) were estimated between all variables. The upper diagonal represents the bivariate associations from LD Score regression. PAU = Problematic Alcohol Use, OUD = Opioid Use Disorder CUD = Cannabis Use Disorder. PTU = Problematic Tobacco Use. FormerSmoke = smoking cessation, AgeSmoke=Age first smoking regularly, MJUse = Marijuana Use, DPW = Drinks Per Week. EverSmoke = Ever Smoking regularly, NE = neuroticism, Risk = Risktaking, EF = ExecutiveFunction, PTSD = Post-**Traumatic Stress** Disorder, TS = Tourette'sSyndrome, OCD = **Obsessive Compulsive** Disorder, GAD = GeneralAnxiety Disorder, MDD = Major Depressive Disorder, BiP = Bipolardisorder, Scz =Schizophrenia, ADHD =




## Supplementary Figure 2. Genetic Correlation Matrix Between Substance Use Disorders.

Genetic correlations (SNP-rG) were estimated between all substance use disorder categories. The upper diagonal represents the bivariate associations from LD Score regression. The lower diagonal are correlations estimated in Genomic Structural Equation Modeling when controlling for common substance use (drinks per week, ever smoking marijuana or tobacco). All genetic correlations were positive (shown in purple). PAU = Problematic Alcohol Use, OUD = Opioid Use Disorder CUD = Cannabis Use Disorder. PTU = Problematic Tobacco Use. All rGs were significant (all p > .01).







**Supplementary Figure 3.** Alternative specification of one factor model, without residual correlation between problematic alcohol use and opioid use disorder.



**Supplemental Figure 4. Full model specification for** *Addiction-rf* **association with non-substance psychopathology.** The top two panels represent the standardized estimates, the bottom two are unstandardized with standard errors. The left panels include the substance use variables as covariates. **Bold\*= p-value < .05.** 



**Supplementary Figure 5.** Alternative model of psychopathology, taken from Grotzinger et al.<sup>2</sup> the left panel represents the model with standardized estimates. The right panel represents the unstandardized estimates with standard errors. **Bold\*= p-value < .05.** 



## Supplemental Figure 6. Model Specification for Mediation Models Linking non-substance

**psychopathology and** *Addiction-rf*. In panel A, we tested whether neurobiological stage-based constructs mediated the association between the *Addiction-rf*-Factor and non-substance psychopathology. In mediation model two, we tested whether neurobiological stage-based constructs had remaining (direct) associations with *Addiction-rf* beyond non-substance psychopathology variables.

## References

- 1. Walters, R. K. *et al.* Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. *Nat. Neurosci.* **21**, 1656–1669 (2018).
- 2. Grotzinger, A. D. *et al.* Genetic architecture of 11 major psychiatric disorders at biobehavioral, functional genomic, and molecular genetic levels of analysis. *medRxiv* vol. 18 18–19 (2020).

